
GigaIO and d-Matrix Advance Strategic Collaboration to Build World's Most Efficient Scalable Inference Solution for Enterprise AI Deployment
CARLSBAD, Calif.--(BUSINESS WIRE)--GigaIO, a pioneer in scalable edge-to-core AI platforms for all accelerators that are easy to deploy and manage, today announced the next phase of its strategic partnership with d-Matrix to deliver the world's most expansive inference solution for enterprises deploying AI at scale. Integrating d-Matrix's revolutionary Corsair inference platform into GigaIO's SuperNODE architecture creates an unparalleled solution that eliminates the complexity and performance bottlenecks traditionally associated with large-scale AI inference deployment.
"Combining GigaIO's scale-up AI architecture with d-Matrix's purpose-built inference acceleration technology delivers unprecedented token generation speeds and memory bandwidth, while significantly reducing power consumption and total cost of ownership."
Share
This joint solution addresses the growing demand from enterprises for high-performance, energy-efficient AI inference capabilities that can scale seamlessly without the typical limitations of multi-node configurations. Combining GigaIO's industry-leading scale-up AI architecture with d-Matrix's purpose-built inference acceleration technology produces a solution that delivers unprecedented token generation speeds and memory bandwidth, while significantly reducing power consumption and total cost of ownership.
Revolutionary Performance Through Technological Integration
The new GigaIO SuperNODE platform, capable of supporting dozens of d-Matrix Corsair accelerators in a single node, is now the industry's most scalable AI inference platform. This integration enables enterprises to deploy ultra-low-latency batched inference workloads at scale without the complexity of traditional distributed computing approaches.
'By combining d-Matrix's Corsair PCIe cards with the industry-leading scale-up architecture of GigaIO's SuperNODE, we've created a transformative solution for enterprises deploying next-generation AI inference at scale,' said Alan Benjamin, CEO of GigaIO. 'Our single-node server eliminates complex multi-node configurations and simplifies deployment, enabling enterprises to quickly adapt to evolving AI workloads while significantly improving their TCO and operational efficiency.'
The combined solution delivers exceptional performance metrics that redefine what's possible for enterprise AI inference:
Processing capability of 30,000 tokens per second at just 2 milliseconds per token for models like Llama3 70B
Up to 10x faster interactive speed compared with GPU-based solutions
3x better performance at a similar total cost of ownership
3x greater energy efficiency for more sustainable AI deployments
'When we started d-Matrix in 2019, we looked at the landscape of AI compute and made a bet that inference would be the largest computing opportunity of our lifetime,' said Sid Sheth, founder and CEO of d-Matrix. 'Our collaboration with GigaIO brings together our ultra-efficient in-memory compute architecture with the industry's most powerful scale-up platform, delivering a solution that makes enterprise-scale generative AI commercially viable and accessible.'
This integration leverages GigaIO's cutting-edge PCIe Gen 5-based AI fabric, which delivers low-latency communication between multiple d-Matrix Corsair accelerators with near-zero latency. This architectural approach eliminates the traditional bottlenecks associated with distributed inference workloads while maximizing the efficiency of d-Matrix's Digital In-Memory Compute (DIMC) architecture, which delivers an industry-leading 150 TB/s memory bandwidth.
Industry Recognition and Performance Validation
This partnership builds on GigaIO's recent achievement of recording the highest tokens per second for a single node in the MLPerf Inference: Datacenter benchmark database, further validating the company's leadership in scale-up AI infrastructure.
'The market has been demanding more efficient, scalable solutions for AI inference workloads that don't compromise performance,' added Benjamin. 'Our partnership with d-Matrix brings together the tremendous engineering innovation of both companies, resulting in a solution that redefines what's possible for enterprise AI deployment.'
Those interested in early access to SuperNODEs running Corsair accelerators can indicate interest here.
About GigaIO
GigaIO redefines scalable AI infrastructure, seamlessly bridging from edge to core with a dynamic, open platform built for every accelerator. Reduce power draw with GigaIO's SuperNODE, the world's most powerful and energy-efficient scale-up AI computing platform. Run AI jobs anywhere with Gryf, the world's first suitcase-sized AI supercomputer that brings datacenter-class computing power directly to the edge. Both are easy to deploy and manage, utilizing GigaIO's patented AI fabric that provides ultra-low latency and direct memory-to-memory communication between GPUs for near-perfect scaling for AI workloads. Visit www.gigaio.com, or follow on Twitter (X) and LinkedIn.
About d-Matrix
d-Matrix is transforming the economics of large-scale inference with the world's most efficient AI computing platform for inference in data centers. The company's Corsair platform leverages innovative Digital In-Memory Compute (DIMC) architecture to accelerate AI inference workloads with industry-leading real-time performance, energy efficiency, and cost savings compared to GPUs and other alternatives. d-Matrix delivers ultra-low latency without compromising throughput, unlocking the next wave of Generative AI use cases while enabling commercially viable AI computing that scales with model size to empower companies of all sizes and budgets. For more information, visit www.d-matrix.ai.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
4 hours ago
- Business Wire
Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025
BEIJING--(BUSINESS WIRE)--Beijing Avistone Biotechnology Co., Ltd ('Avistone'), an innovative biotechnology company focused on precision oncology therapeutics, today announced that the clinical data for Vebreltinib plus Andamertinib (PLB1004), its innovative combination of potent mesenchymal-epithelial transition factor (MET) inhibitor and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. The details of the poster presentation are provided below: Poster title: Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression after failure on EGFR-TKIs treatment: phase Ib/II KYLIN-1 study Abstract Number For Publication: 8632 Session: Poster Session-Lung Cancer- Non-Small Cell Metastatic Location: Poster Board, 112 Session Date/Time: 5/31/2025 1:30pm-4:30pm CDT MET amplification or overexpression is the most common 'off-target' mechanism that drives resistance to EGFR-TKIs in NSCLC patients. The results from Phase Ib/II KYLIN-1 study (NCT06343064) showed that Vebreltinib plus Andamertinib demonstrated notable efficacy and manageable safety in EGFR-mutated NSCLC patients with MET amplification or overexpression after EGFR-TKIs failure. Among the 56 patients enrolled at a dose of Vebreltinib 150mg BID plus Andamertinib 80mg QD (RP2D), the confirmed overall response rate (ORR) was 50.0%, and the median progression-free survival (mPFS) was 9.9 months. In 19 patients with brain metastases, ORR was 42.1% and mPFS was 9.5 months. Grade 3 or higher treatment related adverse events (TRAEs) occurred in 19.6% of the patients. None discontinued treatment or died due to TRAEs. No new safety signal was observed. A multicenter Phase III study, KYLIN-3 study (NCT06970782), is currently ongoing to further evaluate Vebreltinib plus Andamertinib versus platinum-based doublet chemotherapy in patients with EGFR mutations, MET amplification and/or overexpression, locally advanced or metastatic NSCLC following EGFR-TKI failure. To obtain a copy of the poster, please email Avistone. About Vebreltinib Vebreltinib is an orally, potent and selective c-Met inhibitor. Chinese National Medical Products Administration (NMPA) has formally approved the use of Vebreltinib in locally advanced or metastatic NSCLC patients with MET exon 14 skipping mutations, as well as adult patients with isocitrate dehydrogenase mutant astrocytoma with the PTPRZ1-MET fusion gene or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion gene and have failed previous treatments. Currently, Chinese Center for Drug Evaluation (CDE) has formally accepted its New Drug Application (NDA) and granted it priority review, intended for patients with locally advanced or metastatic NSCLC with MET amplification. About Andamertinib (PLB1004) Andamertinib (PLB1004) is an oral, potent, irreversible, and selective EGFR-TKI with potent blood-brain barrier penetration and broad tyrosine kinase activity. Preclinical studies have shown that it can effectively and irreversibly target exon 20 insertion. Additionally, it can also potently target classical EGFR mutations, such as Del19, L858R and T790M with a high degree of selectivity. About Avistone Biotechnology Beijing Avistone Biotechnology Co., Ltd. ('Avistone') is an innovative biotechnology company dedicated to precision therapies with significant unmet medical needs for patients worldwide. Avistone maintains an extensive pipeline of targeted therapies in Non-Small Cell Lung Cancer (NSCLC) and other solid tumors.


Business Wire
6 hours ago
- Business Wire
BIOSIG TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of BioSig Technologies, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed merger of BioSig Technologies, Inc. (NasdaqCM: BSGM) and Streamex Exchange Corporation. Upon closing of the proposed transaction, current BioSig shareholders and holders of common stock equivalents will hold 25% of the fully diluted BioSig common stock outstanding. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to BioSig shareholders. If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit


Business Wire
7 hours ago
- Business Wire
SIGNING DAY SPORTS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Signing Day Sports, Inc.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed merger of Signing Day Sports, Inc. (NYSE: SGN) and One Blockchain LLC. Upon closing of the proposed transaction, Signing Day shareholders are expected to own approximately 8.5% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Signing Day shareholders. If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit